

PRESS RELEASE**DSMB¹ RECOMMENDS THE DISCONTINUATION
OF VO64.08 STUDY (ACTAIR[®] IN CHILDREN)**

Antony, France; 04 July 2011 – 18:00 p.m

Today the DSMB for study VO64.08 (Actair[®] phase III in children) met to review the data of the primary analysis period.

The DSMB has recommended the study be discontinued. In its comments, the DSMB noted that the study population was insufficiently symptomatic to enable differentiation between patients receiving Actair[®] and placebo. Actair[®] was generally well tolerated.

“We are disappointed that the low level of symptoms in children receiving placebo in this study did not allow us to confirm the efficacy of Actair[®] demonstrated in adults.

We remain fully committed to the development of Actair[®] for patients with allergic rhinitis triggered by house dust mites and look forward to the results of the ongoing large scale allergen chamber study expected in Q2 2012” said Albert Saporta, Chairman & CEO of Stallergenes.

This subject will be addressed during the next analysts’ conference call to be held on July 13th, 2011.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical laboratory specialising in treatments by allergenic immunotherapy for the prevention and treatment of allergy-related respiratory conditions, such as severe rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets.

Stallergenes realised 2010 sales of € 216 million, with over 500,000 patients treated with Stallergenes products.

Euronext Paris (Compartment B)
SBF 120.
ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP



¹ Data Safety Monitoring Board (expert group)

For further financial information, please visit our website: <http://www.stallergenes.com>

<p>Contacts Albert Saporta, Chairman and CEO Tel. +33 1 55 59 20 04 Christian Thiry, Chief Financial Officer Tel. +33 1 55 59 20 95 e-mail: investorrelations@stallergenes.fr</p>	<p>Investor and Analyst Relations Lucile de Fraguier, Pavie Finance Tel. +33 1 42 15 04 39 e-mail: contact@pavie-finance.com</p> <p>Stallergenes Press Relations Lise Lemonnier, Senior Communications Director Tel. + 33 1 55 59 20 96 e-mail: llemonnier@stallergenes.fr</p>
---	---